Journey Medical's Emrosi Sales Rise 84% in Third Quarter

The Tip Desk · November 13, 2026 · 3 min read

Emrosi generated $9.0 million in the quarter ended September 30, 2026, as total revenue reached $19.0 million and EBITDA turned positive.

Journey Medical Corporation (DERM), a commercial-stage pharmaceutical company focused on dermatology products, reported total revenues of $19.0 million for the third quarter of 2026, an 8% increase from $17.6 million a year earlier.

The increase was driven by Emrosi, the company’s oral rosacea treatment, which generated $9.0 million in the quarter ended September 30, 2026, up 84% from the third quarter of 2025. Co-Founder, President and Chief Executive Officer Claude Maraoui said the lift was driven by growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans. Emrosi total prescriptions were approximately 40,000 in the third quarter. The company said the number of unique prescribers writing for Emrosi increased again during the quarter and that refill trends on top of new prescription growth were fueling momentum.

Gross margin was 69% for the third quarter of 2026, compared with 67% in the prior-year quarter. Selling, general and administrative expenses were $12.6 million, an increase of $0.5 million from the third quarter of 2025. The company said the rise was primarily due to a one-time expense of $1.7 million recognized upon resolution of a dispute with a former vendor, offset by a reduction in launch-related spending for Emrosi compared with the year-ago quarter.

GAAP net loss narrowed to $1.3 million, or $(0.05) a share basic and diluted, from a net loss of $2.3 million, or $(0.09) a share, a year earlier. EBITDA was $433 thousand for the three months ended September 30, 2026, versus a loss of $468 thousand in the year-ago quarter. Non-GAAP Adjusted EBITDA was $3.5 million, compared with $1.4 million a year earlier.

Year-over-year revenue growth slowed from the two prior quarters. Total revenues were $18.5 million in the second quarter of 2026, a 23% increase from $15.0 million a year earlier, and $16.0 million in the first quarter, a 21% increase from $13.1 million a year earlier. Emrosi revenue was $8.1 million in the second quarter and $6.3 million in the first quarter. Gross margin was 67% in the second quarter and 61.0% in the first quarter, the latter reflecting a $1.3 million non-recurring non-cash charge against cost of goods related to a write-down of API inventory tied to the 2021 Qbrexza asset acquisition. GAAP net loss was $0.3 million, or $(0.01) a share, in the second quarter and $2.2 million, or $(0.08) a share, in the first quarter. Emrosi total prescriptions were approximately 36,000 in the second quarter.

Cash and cash equivalents were $22.3 million at September 30, 2026, compared with $24.1 million at December 31, 2025. Cash had been $25.6 million at June 30, 2026. The company said it had over $22 million in cash and that an expanded sales force and increasing formulary additions with national health plans are expected to facilitate further adoption and market penetration.